Iter-4360dd15-0077-transcript
第 77 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 NEXT_FOCUS PMID 候选 摘要 年龄判据 主要终点"}) → call list_recent({"n":6})
→ call list_by_tag({"limit":10,"tag":"4360dd15"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0059-transcript", "tags": "iteration transcript", "modified": "20260424195947000", "preview": "!! 第 59 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 14 候选 PMID 研究类型 误纳入 original clinical study extension follow-up ancillary\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0076-reflection", "modified": "20260424203004000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424203004000", "tags": "pinned focus"}, {"title": "先用注册库补关键字段", "modified": "20260424203004000", "tags": "lesson abstract-extraction trial-registry endpoint age"}, {"title": "Iter-4360dd15-0076-transcript", "modified": "20260424202956000", "tags": "iteration transcript"}, {"title": "Iter-4360dd15-0075-abstract-field-extraction-two-pmids", "modified": "20260424202951000", "tags": "4360dd15 knowledge fact classification"}, {"title": "Error-20260425-042736", "modified": "20260424202736000", "tags": "error iteration"}]}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "Iter-4360dd15-0075-abstract-field-extraction-two-pmids", "modified": "20260424202951000"}, {"title": "Iter-4360dd15-0072-review-exclusion-first-rule", "modified": "20260424202103000"}, {"title": "Iter-4360dd15-0071-minimal-audit-rules", "modified": "20260424201843000"}, {"title": "Iter-4360dd15-0069-standardized-audit-table-two-trials", "modified": "20260424201621000"}, {"title": "Iter-4360dd15-0068-abstract-endpoint-extraction", "modified": "20260424201407000"}, {"title": "Iter-4360dd15-0067-abstract-endpoints-aging-criteria", "modified": "20260424201141000"}, {"title": "Iter-4360dd15-0066-TierA-abstracts-and-endpoints-for-aging-criteria", "modified": "20260424200925000"}, {"title": "Iter-4360dd15-0065-minimal-relevance-decision-rules-for-retained-mtor-trials", "modified": "20260424200748000"}, {"title": "Iter-4360dd15-0064-relevance-tiering-10-pmids", "modified": "20260424200602000"}, {"title": "Iter-4360dd15-0063-10-pmid-audit-table", "modified": "20260424200432000"}]}
→ call read_note({"title":"NEXT_FOCUS"})
→ call read_note({"title":"Iter-4360dd15-0076-reflection"})
→ call list_tools({})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission `4360dd15` · Iter-0076）\n\n只攻克剩余未确认的最小候选集：逐个补齐研究类型、年龄判据和主要终点三项字段。"}
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0076-reflection", "tags": "iteration reflection", "text": "!! 本轮进展\n本轮通过 ClinicalTrials.gov 和 PMC 补到了 sirolimus 多系统萎缩试验的年龄判据与主要终点字段，并确认可继续按候选 PMID 逐条核验。\n\n!! 失败 / 盲点\n检索路径仍偏发散，多个候选 PMID 没有直接命中摘要，导致本轮没有完成成批字段补全与保留/排除判定。\n\n!! 下轮焦点\n只攻克剩余未确认的最小候选集：逐个补齐研究类型、年龄判据和主要终点三项字段。\n"}
【tool:list_tools】
{"ok": true, "tools": [{"name": "search_memory", "description": "在 TiddlyWiki 长期记忆中按关键字搜索（支持中文空格分隔），返回标题、标签、预览。每轮迭代开始前应先调用以回忆。", "custom": false}, {"name": "read_note", "description": "读取某一条 tiddler 的完整正文。", "custom": false}, {"name": "write_note", "description": "向 TiddlyWiki 写入（或覆盖）一条 tiddler。这是 Sisyphus 的长期记忆入口——每轮至少写一条。建议标签：knowledge, experiment, reflection, plan, idea, fact, question, lesson。TiddlyWiki 标记：!! 小标题，''粗体''，//斜体//，[[其它tiddler]]。", "custom": false}, {"name": "list_recent", "description": "列出最近修改过的 tiddler。", "custom": false}, {"name": "list_by_tag", "description": "按标签列出相关 tiddler。", "custom": false}, {"name": "run_python", "description": "在 workspace/ 下以子进程执行一段 Python 代码，返回 stdout/stderr。用于计算、模拟、验证假设、抓取公开数据（禁止任何破坏性操作）。", "custom": false}, {"name": "read_file", "description": "读取 workspace/ 下的某个文件。", "custom": false}, {"name": "write_file", "description": "向 workspace/ 下写入文件（默认覆盖，append=true 时追加）。", "custom": false}, {"name": "list_files", "description": "列出 workspace/ 下的文件。", "custom": false}, {"name": "web_fetch", "description": "抓取任意公开 URL（GET），返回剥离 HTML 后的纯文本。适合读论文摘要、文档、博客、百科。", "custom": false}, {"name": "web_search", "description": "用 DuckDuckGo 搜索互联网，返回 title/url/snippet 列表。找入口、找链接、调研时用。", "custom": false}, {"name": "wiki_search", "description": "维基百科搜索：返回若干条目的摘要和 URL。lang 默认 en，可传 zh 等。", "custom": false}, {"name": "arxiv_search", "description": "arXiv 论文检索：标题/作者/摘要/链接。理论、数学、物理、CS、bio 类前沿论文的主入口。", "custom": false}, {"name": "pubmed_search", "descriptio
→ call search_memory({"limit":10,"query":"4360dd15 sirolimus PMID 候选 age endpoint"})
→ call search_memory({"limit":10,"query":"4360dd15 35040506"})
→ call read_note({"title":"Iter-4360dd15-0075-abstract-field-extraction-two-pmids"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0059-transcript", "tags": "iteration transcript", "modified": "20260424195947000", "preview": "!! 第 59 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS PMID 10 条候选 研究类型 保留 排除 理由\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0059-transcript", "tags": "iteration transcript", "modified": "20260424195947000", "preview": "!! 第 59 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 PMID 38310895 reference chain Crossref 75 references human trial rapamycin everolimus sirolimus\"}) → call list_recent({\"n\":8}) → call list_tools({}) 【tool:search_m【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0075-abstract-field-extraction-two-pmids", "tags": "4360dd15 knowledge fact classification", "text": "!! 第 76 轮：两个剩余候选 PMID 的摘要级字段抽取\n\n本轮只做一件事：把两个已锁定候选 PMID 的摘要/公开片段中的三个字段补齐：研究类型、年龄判据、主要终点。\n\n!! PMID 35040506\n- 题名：mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis\n- 研究类型：随机、双盲、安慰剂对照、phase II futility trial；并带 1-year biomarker longitudinal analysis\n- 年龄判据：公开临床试验页显示入组年龄 30–80 岁\n- 主要终点：48 周时 UMSARS total score 的变化（change from baseline to week 48）\n- 结论：属于原始临床研究，但疾病指向为 MSA，不是直接的 longevity 研究\n- 证据来源：PubMed 题名；ClinicalTrials.gov/NINDS 摘要片段；Europe PMC/snippet 显示 primary outcome 为 UMSARS total score\n\n!! PMID 29992557\n- 题名：Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial\n- 研究类型：单臂 phase IIIB 试验\n- 年龄判据：postmenopausal women（绝经后女性）\n- 主要终点：progression-free survival (PFS)\n- 结论：属于原始临床研究，但为肿瘤治疗研究，不是直接的 longevity 研究\n- 证据来源：PubMed 题名；公开摘要 snippet 明确写出 PFS 为 primary endpoint\n\n!! 可复现抽取规则\n1. 优先从题名识别 study design（randomized / placebo-controlled / single-arm / phase / futility）。\n2. 年龄判据优先读取公开 trial page 或摘要中的明确人群限定词（如 30–80 岁、postmenopausal women）。\n3. 主要终点优先抓 abstract/公开 snippet 中的 primary endpoint / primary outcome 语句。\n4. 如果研究对象是具体疾病或肿瘤且终点是疾病量表 / PFS，而非寿命、死亡或衰老生物标志物
→ call read_note({"title":"Iter-4360dd15-0076-transcript"})
→ call read_note({"title":"Iter-4360dd15-0069-standardized-audit-table-two-trials"})
→ call read_note({"title":"Iter-4360dd15-0068-abstract-endpoint-extraction"})
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0076-transcript", "tags": "iteration transcript", "text": "!! 第 76 轮执行轨迹\n\n
→ call search_memory({\\\"limit\\\":10,\\\"query\\\":\\\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\\\"}) → call list_recent({\\\"n\\\":10}) → call list_tools({}) 【tool:search_memory】 {\\\"ok\\\": true, \\\"results\\\": [{\\\"title\\\": \\\"Iter-4360dd15-0059-transcript\\\", \\\"tags\\\": \\\"iteration transcript\\\", \\\"modified\\\": \\\"20260424195947000\\\", \\\"preview\\\": \\\"!! 第 59 轮执行轨迹 → call search_memory({\\\"limit\\\":10,\\\"query\\\":\\\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\\\"}) → call list_recent({\\\"n\\\":8}) → call list_by_tag({\\\"limit\\\":20,\\\"tag\\\":\\\"4360dd15\\\"}) 【tool:search_memory】 {\\\"ok\\\": true, \\\"results\\\": [{\\\"title\\\": \\\"Iter-4360dd15-0055-transcript\\\", \\\"tags\\\": \\\"iteration transcript\\\", \\\"modified\\\": \\\"20260424195425000\\\", 【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0069-standardized-audit-table-two-trials", "tags": "4360dd15 knowledge fact method", "text": "!! 第 70 轮：两篇 Tier A 试验的标准化审计表\n\n本轮子任务：把 PMID 33977284 与 PMID 29408453 的摘要/可访问全文中“主要终点 / 年龄判据”压缩成一个可复用的审计表，便于后续批量筛查与分层。\n\n| PMID | 研究题名 | 研究类型 | 年龄判据 / 入组人群 | 主要终点（primary outcome / main endpoint） | 最直接的衰老相关判据 | 审计分类 |\n|---|---|---|---|---|---|---|\n| 33977284 | Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials | phase 2b + phase 3 randomized controlled trials | adults aged at least 65 years；phase 2b 进一步限定 65–85 岁且有慢病/吸烟等风险背景 | phase 2b：16 周冬季冷/流感季的 //laboratory-confirmed RTIs// 发生率；phase 3：//clinically symptomatic respiratory illness// 发生率 | older adults + IFN-induced antiviral gene expression；结局层的 aging proxy 是呼吸道感染负担下降 | //immune-aging / infection-proxy evidence//，不是 longevity endpoint |\n| 29408453 | A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, Physical Performance, and Cognitive Effects | randomized control trial / feasibility pilot | generally healthy older adults aged 70–95 years | 摘要主线是 //feasibility and safety//；主要监测域包括 CBC/CMP/HbA1c/OGTT、认知（EXIT25/SLUMS/TAPS）、体能（handgrip strength、40-foot timed walks）、免疫衰老（cytokines、blood cell subsets） | older adults + cognition/physical performance/inflammation/immune-cell subsets | //geroprotector feasibility/safety pilot//，不是硬终点抗衰老
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0068-abstract-endpoint-extraction", "tags": "4360dd15 knowledge fact method", "text": "!! 第 68 轮：从 PMC 可访问全文抽取两篇试验的 primary outcome 与直接衰老判据\n\n本轮子任务：只做一件事——把 PMID 33977284 与 PMID 29408453 的 //primary outcome// 和最直接的衰老相关判据从可访问全文中定位出来，作为后续审计的可复用证据。\n\n!! PMID 33977284\n'''题名'''：Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials\n\n'''可验证的 primary outcome'''\n- phase 2b primary outcome = 16 周冬季流感/感冒季期间 //laboratory-confirmed RTIs// 的发生率。\n- phase 3 primary outcome = //clinically symptomatic respiratory illness// 的发生率（无论是否实验室确认）。\n\n'''最直接的衰老相关判据'''\n- 纳入标准：''adults aged at least 65 years''。\n- 生物学 aging proxy：IFN-induced antiviral gene expression 的上调。\n- 结果层 aging proxy：RTI 易感性 / 感染负担是否下降。\n- 该试验没有把寿命或疾病自由生存作为终点，因此只能归为 //immune-aging / infection-proxy evidence//，不能夸大为 longevity endpoint。\n\n'''可访问来源'''\n- PMC：https://pmc.ncbi.nlm.nih.gov/articles/PMC8102040/\n- PMID：33977284\n\n!! PMID 29408453\n'''题名'''：A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects\n\n'''可验证的 primary endpoint / 研究主线'''\n- 摘要明确指向 //feasibility and safety//。\n- 监测的主要结果域包括：CBC/CMP/HbA1c/OGTT；认知（EXIT25、SLUMS、TAPS）；体能（handgrip strength、40-foot timed walks）；免疫衰老（pro-inflammatory cytokines、blood cell subsets）。\n\n'''最直接的衰老相关判据'''\n- 纳入对象：''generally healthy older adults (
→ call run_python({"code":"from dataclasses import dataclass\n\npmids = {\n 35040506: {\n 'age':'30-80',\n 'endpoint':'48-week change in UMSARS total score',\n 'type':'randomized double-blind placebo-controlled futility trial',\n },\n 29992557: {\n 'age':'postmenopausal women',\n 'endpoint':'progression-free survival (PFS)',\n 'type':'single-arm phase IIIB trial',\)
→ call define_tool({"name":"classify_trial_longevity_relevance","description":"Classify a clinical trial's relevance to direct longevity evidence using age criterion, study type, and primary endpoint keywords. Useful for repeated audit of PMIDs in the aging/geroprotection review pipeline.","code":"def run(**kwargs):\n \"\"\"kwargs: age_criterion, study_type, primary_endpoint, disease_area(optional)\n returns a)
【tool:run_python】
{"ok": true, "stdout": "35040506 disease_specific_non_longevity\n type: randomized double-blind placebo-controlled futility trial\n age: 30-80\n endpoint: 48-week change in UMSARS total score\n\n29992557 potentially_direct_longevity_or_closer\n type: single-arm phase IIIB trial\n age: postmenopausal women\n endpoint: progression-free survival (PFS)\n\n33977284 aging_proxy_infection_burden\n type: phase 2b + phase 3 randomized trials\n age: at least 65 years\n endpoint: laboratory-confirmed RTIs / clinically symptomatic respiratory illness\n\n29408453 feasibility_safety_pilot\n type: randomized control trial feasibility pilot\n age: 70-95 years\n endpoint: feasibility and safety; immune, cognitive, physical performance measures\n\n", "stderr": "", "returncode": 0}
【tool:define_tool】
{"ok": false, "error": "参数错误: tool_define_tool() missing 1 required positional argument: 'parameters'"}
→ call define_tool({"name":"classify_trial_longevity_relevance","description":"Classify a clinical trial's relevance to direct longevity evidence using age criterion, study type, and primary endpoint keywords. Useful for repeated audit of PMIDs in the aging/geroprotection review pipeline.","code":"def run(**kwargs):\n \"\"\"kwargs: age_criterion, study_type, primary_endpoint, disease_area(optional)\n returns a)
【tool:define_tool】
{"ok": false, "error": "参数错误: tool_define_tool() missing 1 required positional argument: 'parameters'"}
→ call define_tool({"parameters":{"name":"classify_trial_longevity_relevance","description":"Classify a clinical trial's relevance to direct longevity evidence using age criterion, study type, and primary endpoint keywords. Useful for repeated audit of PMIDs in the aging/geroprotection review pipeline.","code":"def run(**kwargs):\n \"\"\"kwargs: age_criterion, study_type, primary_endpoint, disease_area(optional)\)
【tool:define_tool】
{"ok": false, "error": "参数错误: tool_define_tool() missing 3 required positional arguments: 'name', 'description', and 'code'"}
→ call define_tool({"name":"classify_trial_longevity_relevance","description":"Classify a clinical trial's relevance to direct longevity evidence using age criterion, study type, and primary endpoint keywords. Useful for repeated audit of PMIDs in the aging/geroprotection review pipeline.","code":"def run(**kwargs):\n \"\"\"kwargs: age_criterion, study_type, primary_endpoint, disease_area(optional)\n returns a)
【tool:define_tool】
{"ok": false, "error": "参数错误: tool_define_tool() missing 1 required positional argument: 'parameters'"}
→ call define_tool({"parameters":{"name":"classify_trial_longevity_relevance","description":"Classify a clinical trial's relevance to direct longevity evidence using age criterion, study type, and primary endpoint keywords. Useful for repeated audit of PMIDs in the aging/geroprotection review pipeline.","code":"def run(**kwargs):\n \"\"\"kwargs: age_criterion, study_type, primary_endpoint, disease_area(optional)\)
【tool:define_tool】
{"ok": false, "error": "参数错误: tool_define_tool() missing 3 required positional arguments: 'name', 'description', and 'code'"}
→ call run_python({"code":"cases = [\n (35040506, 'randomized double-blind placebo-controlled futility trial', '30-80', '48-week change in UMSARS total score', 'disease_specific_non_longevity'),\n (29992557, 'single-arm phase IIIB trial', 'postmenopausal women', 'progression-free survival (PFS)', 'disease_specific_non_longevity despite survival-like keyword'),\n (33977284, 'phase 2b + phase 3 randomized tr)
【tool:run_python】
{"ok": true, "stdout": "(35040506, 'randomized double-blind placebo-controlled futility trial', '30-80', '48-week change in UMSARS total score', 'disease_specific_non_longevity')\n(29992557, 'single-arm phase IIIB trial', 'postmenopausal women', 'progression-free survival (PFS)', 'disease_specific_non_longevity despite survival-like keyword')\n(33977284, 'phase 2b + phase 3 randomized trials', 'at least 65 years', 'laboratory-confirmed RTIs / clinically symptomatic respiratory illness', 'aging_proxy_infection_burden')\n(29408453, 'randomized control trial feasibility pilot', '70-95 years', 'feasibility and safety; immune, cognitive, physical performance measures', 'feasibility_safety_pilot')\n", "stderr": "", "returncode": 0}
→ call write_note({"tags":["4360dd15","knowledge","fact","method"],"text":"!! 第 77 轮：剩余候选 PMID 的统一 longevity 相关性分类\n\n本轮把已补齐字段的候选按统一阈值做了最终定位，避免继续在题名层面漂移。\n\n!! 分类规则（简化版）\n- 主要终点包含 //survival / mortality / death / lifespan / healthspan / disease-free / disability-free//，可视为更接近直接 longevity 证据。\n- 主要终点包含 //feasibility / safety//，归为 //feasibility_safety_pilot//。\n- 主要终点是 //infection / respiratory illness / RTI//，归为 //a)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\Iter-4360dd15-0077-unified-longevity-classification-four-pmids.tid", "title": "Iter-4360dd15-0077-unified-longevity-classification-four-pmids"}
【assistant】
本轮已完成：
- 对剩余 4 个候选 PMID 做了统一阈值分类
- 区分了：
- `disease_specific_non_longevity`
- `aging_proxy_infection_burden`
- `feasibility_safety_pilot`
- 纠正了一个关键反事实：`progression-free survival (PFS)` 不能自动算作长寿证据，它在肿瘤语境里仍是疾病控制终点
- 已写入长期记忆：
- `Iter-4360dd15-0077-unified-longevity-classification-four-pmids`
当前最值得推进的最窄子问题是：把尚未覆盖的候选 PMID 继续按同一规则补齐，直到形成“剩余候选全集”的最终保留/排除表。
<NEXT_FOCUS>只找还没进入四分类表的候选 PMID，逐个补齐研究类型、年龄判据和主要终点，然后一口气做最终保留/排除。</NEXT_FOCUS>